An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration

Linda J Chan, Orlagh M. Feeney, Nathania J. Leong, Victoria M. McLeod, Christopher J H Porter, Charlotte C Williams, Lisa M Kaminskas

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer. Two PEGylated variants of interferon α2 (containing 12 and 40 kDa PEGs) are currently marketed and display longer plasma circulation times than that of unmodified interferon. With increasing realization that the lymphatic system plays an important role in the extrahepatic replication of the hepatitis C virus and in the metastatic dissemination of cancers, this study sought to evaluate PEGylation strategies to optimally enhance the antiviral activity and plasma and lymphatic exposure of interferon after subcutaneous administration in rats. The results showed that conjugation with a linear 20 kDa PEG provided the most ideal balance between activity and plasma and lymph exposure. A linear 5 kDa PEG variant also exhibited excellent plasma and lymph exposure to interferon activity when compared to those of unmodified interferon and the clinically available linear 12 kDa PEGylated construct.

Original languageEnglish
Pages (from-to)2866-2875
Number of pages10
JournalBiomacromolecules
Volume18
Issue number9
DOIs
Publication statusPublished - 11 Sep 2017

Cite this

@article{02683cea496448b3814306fdb9b950a7,
title = "An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration",
abstract = "Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer. Two PEGylated variants of interferon α2 (containing 12 and 40 kDa PEGs) are currently marketed and display longer plasma circulation times than that of unmodified interferon. With increasing realization that the lymphatic system plays an important role in the extrahepatic replication of the hepatitis C virus and in the metastatic dissemination of cancers, this study sought to evaluate PEGylation strategies to optimally enhance the antiviral activity and plasma and lymphatic exposure of interferon after subcutaneous administration in rats. The results showed that conjugation with a linear 20 kDa PEG provided the most ideal balance between activity and plasma and lymph exposure. A linear 5 kDa PEG variant also exhibited excellent plasma and lymph exposure to interferon activity when compared to those of unmodified interferon and the clinically available linear 12 kDa PEGylated construct.",
author = "Chan, {Linda J} and Feeney, {Orlagh M.} and Leong, {Nathania J.} and McLeod, {Victoria M.} and Porter, {Christopher J H} and Williams, {Charlotte C} and Kaminskas, {Lisa M}",
year = "2017",
month = "9",
day = "11",
doi = "10.1021/acs.biomac.7b00794",
language = "English",
volume = "18",
pages = "2866--2875",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society (ACS)",
number = "9",

}

An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. / Chan, Linda J; Feeney, Orlagh M.; Leong, Nathania J.; McLeod, Victoria M.; Porter, Christopher J H; Williams, Charlotte C; Kaminskas, Lisa M.

In: Biomacromolecules, Vol. 18, No. 9, 11.09.2017, p. 2866-2875.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration

AU - Chan, Linda J

AU - Feeney, Orlagh M.

AU - Leong, Nathania J.

AU - McLeod, Victoria M.

AU - Porter, Christopher J H

AU - Williams, Charlotte C

AU - Kaminskas, Lisa M

PY - 2017/9/11

Y1 - 2017/9/11

N2 - Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer. Two PEGylated variants of interferon α2 (containing 12 and 40 kDa PEGs) are currently marketed and display longer plasma circulation times than that of unmodified interferon. With increasing realization that the lymphatic system plays an important role in the extrahepatic replication of the hepatitis C virus and in the metastatic dissemination of cancers, this study sought to evaluate PEGylation strategies to optimally enhance the antiviral activity and plasma and lymphatic exposure of interferon after subcutaneous administration in rats. The results showed that conjugation with a linear 20 kDa PEG provided the most ideal balance between activity and plasma and lymph exposure. A linear 5 kDa PEG variant also exhibited excellent plasma and lymph exposure to interferon activity when compared to those of unmodified interferon and the clinically available linear 12 kDa PEGylated construct.

AB - Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer. Two PEGylated variants of interferon α2 (containing 12 and 40 kDa PEGs) are currently marketed and display longer plasma circulation times than that of unmodified interferon. With increasing realization that the lymphatic system plays an important role in the extrahepatic replication of the hepatitis C virus and in the metastatic dissemination of cancers, this study sought to evaluate PEGylation strategies to optimally enhance the antiviral activity and plasma and lymphatic exposure of interferon after subcutaneous administration in rats. The results showed that conjugation with a linear 20 kDa PEG provided the most ideal balance between activity and plasma and lymph exposure. A linear 5 kDa PEG variant also exhibited excellent plasma and lymph exposure to interferon activity when compared to those of unmodified interferon and the clinically available linear 12 kDa PEGylated construct.

UR - http://www.scopus.com/inward/record.url?scp=85029220083&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.7b00794

DO - 10.1021/acs.biomac.7b00794

M3 - Article

VL - 18

SP - 2866

EP - 2875

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 9

ER -